Circulating sTWEAK and its scavenger receptor sCD163
concentrations in patients with Behçet’s disease

akcan, buket; Aksan, Burak; Orem, Asım; VANİZOR KURAL, Birgül; BAHADIR, Sevgi; aksu arıca, deniz; BALABAN YUCESAN, Fulya; OZER YAMAN, SERAP

doi:10.14744/ijmb.2022.98700

Circulating sTWEAK and its scavenger receptor sCD163 concentrations in patients with Behçet’s disease

Fulya Balaban YUCESAN, (Karadeniz Teknik Üniversitesi Tıp Fakültesi, Tıbbi Biyokimya Anabilim Dalı, Trabzon, Türkiye)

Asım ÖREM, (Karadeniz Teknik Üniversitesi Tıp Fakültesi, Tıbbi Biyokimya Anabilim Dalı, Trabzon, Türkiye)

Deniz Aksu ARICA, (Karadeniz Teknik Üniversitesi Tıp Fakültesi, Dermatoloji Anabilim Dalı, Trabzon, Türkiye)

Burak AKSAN, (Giresun Üniversitesi Tıp Fakültesi, Dermatoloji Anabilim Dalı, Giresun, Türkiye)

Serap Ozer YAMAN, (Karadeniz Teknik Üniversitesi Tıp Fakültesi, Tıbbi Biyokimya Anabilim Dalı, Trabzon, Türkiye)

Buket AKCAN, (Ardahan Üniversitesi Sağlık Bilimleri Fakültesi, Hemşirelik Bölümü, Ardahan, Türkiye)

Birgül VANİZOR KURAL, (Karadeniz Teknik Üniversitesi Tıp Fakültesi, Tıbbi Biyokimya Anabilim Dalı, Trabzon, Türkiye)

Sevgi BAHADIR (Karadeniz Teknik Üniversitesi Tıp Fakültesi, Dermatoloji Anabilim Dalı, Trabzon, Türkiye)

International Journal of Medical Biochemistry

0 0

Yıl: 2022 Cilt: 5 Sayı: 2 Sayfa Aralığı: 89 - 95 Metin Dili: İngilizce DOI: 10.14744/ijmb.2022.98700 İndeks Tarihi: 18-06-2022

Circulating sTWEAK and its scavenger receptor sCD163 concentrations in patients with Behçet’s disease

Öz:

Objectives: Behçet’s disease (BD) is a chronic multisystemic inflammatory disorder and is associated with many inflammatory processes. The present study aimed to examine the serum levels of proinflammatory cytokine soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and its scavenger receptor soluble cluster of differentiation 163 (sCD163) simultaneously in patients with BD by considering their relationships with disease activity. Methods: The study group included 53 patients with BD (29 females and 24 males) and 30 healthy individuals. Patients with a lesion or active organ involvement were defined as active (n=39) and those without were identified as inactive (n=14). Serum sTWEAK and sCD163 concentrations were determined by enzyme-linked immunosorbent assay. Results: Serum sTWEAK and sCD163 levels were significantly increased in patients with BD compared with the healthy group (p=0.016 and p=0.003, respectively). Concentrations of these two molecules were also higher in active and inactive BD than the healthy individuals (p=0.043 for sTWEAK and p=0.010 for sCD163). Receiver operating characteristic curve analysis revealed that serum sCD163 and sTWEAK levels had a discriminating ability between patients with BD and healthy controls with area under the curve values of 0.706 and 0.661, respectively. Conclusion: It was concluded that circulating sTWEAK and its scavenger receptor sCD163 levels were increased in BD, significantly predicted the disease, and might be significant molecules to assess inflammation.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Yazıcı Y, Yazıcı H, editors. Behcet’s Syndrome. New York: Springer; 2010.
2. Leccese P, Alpsoy E. Behçet's Disease: An Overview of Etiopathogenesis. Front Immunol 2019;10:1067.
3. Gül A. Pathogenesis of Behçet's disease: autoinflammatory features and beyond. Semin Immunopathol 2015;37(4):413–8.
4. Becatti M, Emmi G, Bettiol A, Silvestri E, Di Scala G, Taddei N, et al. Behçet's syndrome as a tool to dissect the mechanisms of thrombo-inflammation: clinical and pathogenetic aspects. Clin Exp Immunol 2019;195(3):322–33.
5. Zhou ZY, Chen SL, Shen N, Lu Y. Cytokines and Behcet's disease. Autoimmun Rev 2012;11(10):699–704.
6. Greco A, De Virgilio A, Ralli M, Ciofalo A, Mancini P, Attanasio G, et al. Behçet's disease: New insights into pathophysiology, clinical features and treatment options. Autoimmun Rev 2018;17(6):567–75.
7. Menyawi ME, Fawzy M, Al-Nahas Z, Edris A, Hussein H, Shaker O, et al. Serum tumor necrosis factor alpha (TNF-a) level in patients with Behçet’s disease: Relation to clinical manifestations and disease activity. Egypt Rheumatol 2014;36:139–43.
8. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza MH, Ayed K. Cytokine profile in Behçet's disease patients. Scand J Rheumatol 2002;31(4):205–10.
9. Mendes D, Correia M, Barbedo M, Vaio T, Mota M, Gonçalves O, et al. Behçet's disease--a contemporary review. J Autoimmun 2009;32(3–4):178–88.
10. Pay S, Şimşek I, Erdem H, Dinç A. Immunopathogenesis of Behçet’s disease with special emphasize to the possible role of antigen presenting cells. Rheumatol Int 2007;27:417–24.
11. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104:487–501.
12. Bodmer J, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002;27:19–26.
13. Nakhjavani MR, Abediazar S, Ghorbanihaghjo A, Esmaeili N, Pourlak T, Zununi Vahed S. Serum tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and IL-17 levels are associated with disease activity in systemic lupus erythematosus patients with and without nephritis. J Renal Inj Prev 2019;8(3):204–10.
14. Park MC, Chung SJ, Park YB, Lee SK. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis. Scand J Rheumatol 2008;37(3):173–8.
15. Kaplan M, Yuksel M, Ates I, Yalın Kilic ZM, Kilic H, Ates H, et al. Are sTWEAK and IL-17A levels in ınflammatory bowel disease associated with disease activity and etiopathogenesis? Inflamm Bowel Dis 2016;22(3):615–22.
16. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997;272(51):32401–10.
17. Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 2003;14(3–4):241–9.
18. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008;7(5):411–25.
19. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007;40(1):1–16.
20. Han S, Yoon K, Lee K, Kim K, Jang H, Lee NK, et al. TNF-related weak inducer of apoptosis receptor, a TNF receptor superfamily member, activates NF-kappa B through TNF receptor- associated factors. Biochem Biophys Res Commun 2003;305(4):789–96.
21. Brown SA, Ghosh A, Winkles JA. Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway. J Biol Chem 2010;285(23):17432–41.
22. Blanco-Colio LM, Martín-Ventura JL, Muñóz-García B, Orbe J, Páramo JA, Michel JB, et al. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27(4):916–22.
23. Jelić-Ivanović Z, Bujisić N, Spasić S, Bogavac-Stanojević N, Spasojević-Kalimanovska V, Kotur-Stevuljević J. Circulating sTWEAK improves the prediction of coronary artery disease. Clin Biochem 2009;42(13–14):1381–6.
24. Chorianopoulos E, Jarr K, Steen H, Giannitsis E, Frey N, Katus HA. Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome. Atherosclerosis 2010;211(1):322–6.
25. Wang H, Wang S, Li L, Wang X, Liu C, Lu M, et al. Involvement of the cytokine TWEAK in the pathogenesis of psoriasis vulgaris, pustular psoriasis, and erythrodermic psoriasis. Cytokine 2021;138:155391.
26. Mirioglu S, Cinar S, Yazici H, Ozluk Y, Kilicaslan I, Gul A, et al. Serum and urine TNF-like weak inducer of apoptosis, monocyte chemoattractant protein-1 and neutrophil gelatinase-associated lipocalin as biomarkers of disease activity in patients with systemic lupus erythematosus. Lupus 2020;29(4):379–88.
27. Vendrell J, Chacón MR. TWEAK: A New Player in Obesity and Diabetes. Front Immunol 2013;4:488.
28. Ma HY, Chen S, Cao WD, Min CT. Diagnostic value of TWEAK for predicting active lupus nephritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Ren Fail 2021;43(1):20–31.
29. Van Gorp H, Delputte PL, Nauwynck HJ. Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol 2010;47(7–8):1650–60.
30. Moreno JA, Muñoz-García B, Martín-Ventura JL, Madrigal- Matute J, Orbe J, Páramo JA, et al. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis 2009;207(1):103–10.
31. Graversen JH, Madsen M, Moestrup SK. CD163: a signal receptor scavenging haptoglobin-hemoglobin complexes from plasma. Int J Biochem Cell Biol 2002;34(4):309–14.
32. Fabriek BO, Dijkstra CD, van den Berg TK. The macrophage scavenger receptor CD163. Immunobiology 2005;210(2– 4):153–60.
33. Bover LC, Cardó-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, et al. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol 2007;178(12):8183–94.
34. Møller HJ. Soluble CD163. Scand J Clin Lab Invest 2012;72(1):1– 13.
35. Semnani-Azad Z, Blanco Mejia S, Connelly PW, Bazinet RP, Retnakaran R, Jenkins DJA, et al. The association of soluble CD163, a novel biomarker of macrophage activation, with type 2 diabetes mellitus and its underlying physiological disorders: A systematic review. Obes Rev 2021;22(9):e13257.
36. Skytthe MK, Graversen JH, Moestrup SK. Targeting of CD163+ Macrophages in ınflammatory and malignant diseases. Int J Mol Sci 2020;21(15):5497.
37. Moreno JA, Dejouvencel T, Labreuche J, Smadja DM, Dussiot M, Martin-Ventura JL, et al. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Arterioscler Thromb Vasc Biol 2010;30(6):1253–62.
38. Mrak D, Zierfuss B, Höbaus C, Herz CT, Pesau G, Schernthaner GH. Evaluation of sCD163 and sTWEAK in patients with stable peripheral arterial disease and association with disease severity as well as long-term mortality. Atherosclerosis 2021;317:41–6.
39. Ilter A, Orem C, Balaban Yucesan F, Sahin M, Hosoglu Y, Kurumahmutoglu E, et al. Evaluation of serum sTWEAK and sCD163 levels in patients with acute and chronic coronary artery disease. Int J Clin Exp Med 2015;8(6):9394–402.
40. Ptaszynska-Kopczynska K, Marcinkiewicz-Siemion M, Lisowska A, Waszkiewicz E, Witkowski M, Jasiewicz M, et al. Alterations of soluble TWEAK and CD163 concentrations in patients with chronic heart failure. Cytokine 2016;80:7–12.
41. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990;335(8697):1078–80. 42. Türsen Ü. Activation Markers in Behcet Disease. Türkderm 2009;43(2):74–86.
43. Icli A, Cure MC, Cure E, Arslan S, Unal M, Sakiz D, et al. Soluble tumor necrosis factor (TNF)-like weak ınducer of apoptosis (Tweak) ındependently predicts subclinical atherosclerosis in Behcet's Disease. Acta Medica (Hradec Kralove) 2018;61(3):86– 92.
44. Abu El-Asrar AM, Berghmans N, Al-Obeidan SA, Gikandi PW, Opdenakker G, Van Damme J, et al. Soluble cytokine receptor levels in aqueous humour of patients with specific autoimmune uveitic entities: sCD30 is a biomarker of granulomatous uveitis. Eye 2020;34(9):1614–23.
45. Lopalco G, Lucherini OM, Lopalco A, Venerito V, Fabiani C, Frediani B, et al. Cytokine signatures in mucocutaneous and ocular Behçet's Disease. Front Immunol 2017;8:200.
46. Liu Y, Peng L, Li L, Liu C, Hu X, Xiao S, et al. TWEAK/Fn14 Activation contributes to the pathogenesis of bullous pemphigoid. J Invest Dermatol 2017;137(7):1512–22.
47. Etzerodt A, Rasmussen MR, Svendsen P, Chalaris A, Schwarz J, Galea I, et al. Structural basis for inflammation-driven shedding of CD163 ectodomain and tumor necrosis factor-α in macrophages. J Biol Chem 2014;289(2):778–88.

APA	BALABAN YUCESAN F, Orem A, aksu arıca d, Aksan B, OZER YAMAN S, akcan b, VANİZOR KURAL B, BAHADIR S (2022). Circulating sTWEAK and its scavenger receptor sCD163 concentrations in patients with Behçet’s disease. , 89 - 95. 10.14744/ijmb.2022.98700
Chicago	BALABAN YUCESAN Fulya,Orem Asım,aksu arıca deniz,Aksan Burak,OZER YAMAN SERAP,akcan buket,VANİZOR KURAL Birgül,BAHADIR Sevgi Circulating sTWEAK and its scavenger receptor sCD163 concentrations in patients with Behçet’s disease. (2022): 89 - 95. 10.14744/ijmb.2022.98700
MLA	BALABAN YUCESAN Fulya,Orem Asım,aksu arıca deniz,Aksan Burak,OZER YAMAN SERAP,akcan buket,VANİZOR KURAL Birgül,BAHADIR Sevgi Circulating sTWEAK and its scavenger receptor sCD163 concentrations in patients with Behçet’s disease. , 2022, ss.89 - 95. 10.14744/ijmb.2022.98700
AMA	BALABAN YUCESAN F,Orem A,aksu arıca d,Aksan B,OZER YAMAN S,akcan b,VANİZOR KURAL B,BAHADIR S Circulating sTWEAK and its scavenger receptor sCD163 concentrations in patients with Behçet’s disease. . 2022; 89 - 95. 10.14744/ijmb.2022.98700
Vancouver	BALABAN YUCESAN F,Orem A,aksu arıca d,Aksan B,OZER YAMAN S,akcan b,VANİZOR KURAL B,BAHADIR S Circulating sTWEAK and its scavenger receptor sCD163 concentrations in patients with Behçet’s disease. . 2022; 89 - 95. 10.14744/ijmb.2022.98700
IEEE	BALABAN YUCESAN F,Orem A,aksu arıca d,Aksan B,OZER YAMAN S,akcan b,VANİZOR KURAL B,BAHADIR S "Circulating sTWEAK and its scavenger receptor sCD163 concentrations in patients with Behçet’s disease." , ss.89 - 95, 2022. 10.14744/ijmb.2022.98700
ISNAD	BALABAN YUCESAN, Fulya vd. "Circulating sTWEAK and its scavenger receptor sCD163 concentrations in patients with Behçet’s disease". (2022), 89-95. https://doi.org/10.14744/ijmb.2022.98700

APA	BALABAN YUCESAN F, Orem A, aksu arıca d, Aksan B, OZER YAMAN S, akcan b, VANİZOR KURAL B, BAHADIR S (2022). Circulating sTWEAK and its scavenger receptor sCD163 concentrations in patients with Behçet’s disease. International Journal of Medical Biochemistry, 5(2), 89 - 95. 10.14744/ijmb.2022.98700
Chicago	BALABAN YUCESAN Fulya,Orem Asım,aksu arıca deniz,Aksan Burak,OZER YAMAN SERAP,akcan buket,VANİZOR KURAL Birgül,BAHADIR Sevgi Circulating sTWEAK and its scavenger receptor sCD163 concentrations in patients with Behçet’s disease. International Journal of Medical Biochemistry 5, no.2 (2022): 89 - 95. 10.14744/ijmb.2022.98700
MLA	BALABAN YUCESAN Fulya,Orem Asım,aksu arıca deniz,Aksan Burak,OZER YAMAN SERAP,akcan buket,VANİZOR KURAL Birgül,BAHADIR Sevgi Circulating sTWEAK and its scavenger receptor sCD163 concentrations in patients with Behçet’s disease. International Journal of Medical Biochemistry, vol.5, no.2, 2022, ss.89 - 95. 10.14744/ijmb.2022.98700
AMA	BALABAN YUCESAN F,Orem A,aksu arıca d,Aksan B,OZER YAMAN S,akcan b,VANİZOR KURAL B,BAHADIR S Circulating sTWEAK and its scavenger receptor sCD163 concentrations in patients with Behçet’s disease. International Journal of Medical Biochemistry. 2022; 5(2): 89 - 95. 10.14744/ijmb.2022.98700
Vancouver	BALABAN YUCESAN F,Orem A,aksu arıca d,Aksan B,OZER YAMAN S,akcan b,VANİZOR KURAL B,BAHADIR S Circulating sTWEAK and its scavenger receptor sCD163 concentrations in patients with Behçet’s disease. International Journal of Medical Biochemistry. 2022; 5(2): 89 - 95. 10.14744/ijmb.2022.98700
IEEE	BALABAN YUCESAN F,Orem A,aksu arıca d,Aksan B,OZER YAMAN S,akcan b,VANİZOR KURAL B,BAHADIR S "Circulating sTWEAK and its scavenger receptor sCD163 concentrations in patients with Behçet’s disease." International Journal of Medical Biochemistry, 5, ss.89 - 95, 2022. 10.14744/ijmb.2022.98700
ISNAD	BALABAN YUCESAN, Fulya vd. "Circulating sTWEAK and its scavenger receptor sCD163 concentrations in patients with Behçet’s disease". International Journal of Medical Biochemistry 5/2 (2022), 89-95. https://doi.org/10.14744/ijmb.2022.98700